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Context: Plasma YKL-40 is elevated in patients with type 2 diabetes. The potential role of visceral
adipose tissue (VAT) as a significant source of YKL-40 is unknown.
Objective: In the study circulating andexpression levels of YKL-40were examined inVATanalyzing
the contributionofadipocytes and stromovascular fraction cells (SVFCs).WealsoexploredYKL-40’s
implication in insulin resistance and inflammation and the effect of weight loss on plasma YKL-40
concentrations.
PatientsandMethods:Samplesobtained from53subjectswereused in the study.Geneandprotein
expression levels of YKL-40 were analyzed in VAT as well as in both adipocytes and SVFCs. In
addition, circulating YKL-40 concentrations weremeasured before and after weight loss achieved
either by Roux-en-Y gastric bypass (n  26) or after a conventional dietetic program (n  20).
Results:Circulating concentrations andVATexpression of YKL-40were increased in obese patients
with type 2 diabetes (P  0.01) as well as associated with variables of insulin resistance and in-
flammation. No differences in YKL-40 expression levels between adipocytes and SVFCs were de-
tected. Monocyte chemoattractant protein-1 and homeostasis model assessment emerged (P 
0.01) as independent factors predicting circulating YKL-40. Elevated levels of YKL-40 in obese
patients decreased after weight loss following a conventional hypocaloric diet (P 0.05) but not
via a surgery-induced negative energy balance mediated by the Roux-en-Y gastric bypass.
Conclusions: The association of increased YKL-40 mRNA and protein levels in VAT with its circu-
lating concentrations indicates an important contribution of VAT in YKL-40 regulation. Further-
more, our data suggest a relevant role of glucose metabolism and inflammation on YKL-40
regulation. (J Clin Endocrinol Metab 96: 200–209, 2011)
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Abdominal obesity is a well-established metabolic riskfactor for the development of insulin resistance and
type 2 diabetes (T2D). Compelling evidence points to ex-
cess visceral adipose tissue (VAT) accumulation dysregu-
lating the adipokine secretion profile, which results in ad-
verse effects on glucose and lipid metabolism as well as
inflammation, with the latter representing a key etiolog-
ical factor in linking increased adiposity with T2D devel-
opment (1, 2).
YKL-40, also known as cartilage glycoprotein-39 or
chitinase-3-like-1 is a 40-kDa heparin- and chitin-binding
lectin member of the mammalian chitinase-like protein
family without glycolytic properties (3). YKL-40 is ex-
pressed and secreted by several cell types of the innate
immune system and by differentiated vascular endothelial
and smooth muscle cells (4). A substantial body of evi-
dence indicates that YKL-40 acts not only as an inflam-
matory marker in relation to both acute and chronic in-
flammation but also as a growth factor with involvement
in extracellularmatrix remodelingandangiogenesis (5). In
this regard, YKL-40 was found to be associated with var-
ious inflammatory conditions such as rheumatoiddiseases
and cancer (6) and also in early stages of atherosclerosis
(5). Noteworthy, YKL-40 is a growth factor with func-
tions in cancer and cell proliferation (4, 7). In this sense,
our group has shown increased YKL40 gene expression
levels in VAT of patients with colon cancer (8). In addi-
tion, the participation of YKL-40 in vascular processes
implies that YKL-40 may play a role in endothelial dys-
function and atherosclerosis (7). A strong association of
YKL-40with the inflammatory cytokines IL-6 andmono-
cyte chemoattractant protein-1 (MCP-1) has been also de-
scribed (9, 10). Previous studies have reported that pa-
tients with T2D exhibit elevated plasma levels of YKL-40
compared with healthy control subjects independently of
obesity and a positive association with fasting glucose,
insulin, and the homeostatic model assessment (HOMA)
index has been also detected (9–11). In this sense, circu-
lating levels of YKL-40 are also reportedly elevated in
patients with type 1 diabetes (12).
Subcutaneous adipose tissue (SAT) reportedly exhibits
a positive correlation of YKL-40 gene expression levels
with its circulating concentrations (9). A large body of
evidence shows that increased VAT is associated with a
higher risk of developing obesity-related comorbidities
than elevated SAT (13, 14). Nonetheless, YKL-40 gene
and protein expression levels have not been analyzed be-
fore inVAT.Theaimof thepresent studywas todetermine
gene and protein expression levels of YKL-40 in VAT to-
gether with plasma concentrations in healthy control sub-
jects, obese normoglycemic (NG) individuals and obese
patients with T2D. We also examined the relation of
YKL-40 with key genes and circulating proteins involved
in inflammation. ElevatedYKL-40 concentrations inmor-
bid obesity have been previously shown to decrease after
bariatric surgery-induced weight loss (10). The present
study assessed and compared the effect of weight loss
achieved either by Roux-en-Y gastric bypass (RYGB) or a
conventional dietetic program on plasma YKL-40 levels.
Patients and Methods
For detailed Research Design and Methods, see Supplemental
Patients and Methods, published on The Endocrine Society’s
Journals Online web site at http://jcem.endojournals.org.
Patient selection
To analyze the effect of obesity and T2D on YKL-40 concen-
trations, 53 subjects were recruited from healthy volunteers and
patients attending the Departments of Endocrinology and Sur-
gery at the Clínica Universidad de Navarra. Furthermore, gene
and protein expression levels of YKL-40 andCD68 inVATwere
assessed in a subgroup of subjects (n 29). In addition, a group
of 46 obese female patients was selected to investigate the effect
of weight loss on circulating concentrations of YKL-40. The
weight losswasachievedbyeitherRYGB[n26, evaluatedafter
both a short (14 wk) and long term (13 months) period] or by
prescription of a diet (n 20, evaluated after 14 wk) providing
a daily energy deficit of 500-1000 kcal/d as calculated from the
determination of the resting energy expenditure through indirect
calorimetry (Vmax29; SensorMedics Corp., Yorba Linda, CA)
and multiplication by the physical activity level factor to obtain
the individual’s total energy expenditure. Biochemical assays of
subjects included in the study as well as transcript and protein
levels for YKL-40 were measured as previously described (15).
Statistical analysis
Data are presented as mean  SEM. Differences between
groups were assessed by one-way ANOVA followed by Bonfer-
roni’s post hoc tests, two-tailed unpaired Student’s t tests, and
two-tailed paired t tests as appropriate. Pearson’s correlation
coefficients (r)wereused to analyze the associationbetweenvari-
ables. The calculationswere performed using the SPSS/Windows
version 15.0 statistical package (SPSS, Chicago, IL). P  0.05
was considered statistically significant.
Results
YKL-40 levels are elevated in human
obesity-associated 2TD
The biochemical and hormonal characteristics of the
subjects included in the study are shown in Table 1. Sig-
nificant differences in circulating YKL-40 concentrations
between the three experimental groups were observed
(P  0.002). Plasma YKL-40 levels were significantly in-
creased in obese patients taken as a whole (18.9 5.3 vs.
31.93.7pg/ml;P0.004) comparedwith lean subjects.
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Furthermore, YKL-40 levels were higher in obese patients
with T2D comparedwith both lean (P 0.003) and obese
NG volunteers (P  0.013) (Fig. 1A). Visceral obesity is
reflected by an elevated waist-to-hip ratio (WHR). To in-
vestigate the relation between circulatingYKL-40 concen-
trations and visceral adiposity, the whole study popula-
tion was divided into three categories by tertiles of WHR.
Patients in the top WHR tertile exhibited significantly
higher circulating YKL-40 concentrations compared with
patients included in the bottom tertile (36.9  6.5 vs.
20.7 1.7 pg/ml; P 0.043). PlasmaYKL-40 levels were
positively associated (P  0.01) with fasting glucose and
insulin concentrations as well as with the HOMA index
and negatively correlated with the quantitative insulin
sensitivity check index (QUICKI) (Table 2). Glycosylated
hemoglobin levels corresponding to the group of obese
T2D patients were 8.3  2.4% (n  8). No association
between circulating concentrations of glycosylated hemo-
globin and YKL-40 were detected (r  0.31; P  0.503).
No differences in the circulating and urinary levels of
creatinine were detected between groups. Although the
glomerular filtration rate (GFR) was lower in patients
withT2D, thedifferences fell outof statistical significance.
YKL-40 concentrations were positively associated with
TABLE 1. Anthropometric and biochemical characteristics of subjects included in the study
Lean Obese NG Obese T2D
n 16 20 17
Age (yr) 32  4 34  2 49  3a
BMI (kg/m2) 20.1  0.7 44.0  1.3b 47.0  2.4b
Body fat (%) 25.5  1.8 53.8  0.9b 54.1  1.2b
Waist (cm) 66.7  1.8 112.8  3.6b 130.5  4.7b,c
WHR 0.75  0.01 0.86  0.02a 0.90  0.02b
Fasting glucose (mg/dl) 84.8  5.0 90.7  3.2 131.2  12.9b,d
2-h OGTT glucose (mg/dl) 101.0  14.1 120.0  8.4 238.1  37.5b,d
Fasting insulin (U/ml) 6.4  1.2 12.8  1.7 28.5  4.1b,d
2-h OGTT insulin (U/ml) 8.5  1.9 87.5  13.9 132.6  33.5b,d
HOMA 1.4  0.3 2.9  0.4 9.8  2.4b,d
QUICKI 0.38  0.02 0.33  0.01b 0.29  0.01b,d
Triglycerides (mg/dl) 69  10 98  8 130  14a
Cholesterol (mg/dl) 176  10 194  10 202  11
LDL cholesterol (mg/dl) 102  11 130  9 129  12
HDL cholesterol (mg/dl) 61  4 44  2b 48  5a
Leptin (ng/ml) 8.3  1.6 64.7  7.0b 67.3  7.0b
Adiponectin (g/ml) 21.4  5.4 8.1  1.2a 10.0  0.6a
Uric acid (mg/dl) 4.0  0.2 5.1  0.3 5.9  0.4b
Plasma creatinine (mg/dl) 0.76  0.02 0.71  0.02 0.78  0.04
Urinary creatinine (mg/dl) — 130.6  10.0 146.4  21.8
GFR 99.2  3.4 101.9  4.3 88.1  7.4
CRP (mg/liter) 1.1  0.3 8.4  1.3b 13.3  3.9b
Fibrinogen (mg/dl) 208  24 363  27b 385  25b
vWF (%) 65  10 97  12 125  17a
Homocysteine (mol/liter) 6.8  0.9 6.8  0.5 8.3  0.6
SAA (g/ml) 16.1  4.8 54.4  9.1a 33.0  10.4
IL-6 (pg/ml) 1.6  0.1 2.5  0.2b 2.8  0.3b
IL-8 (pg/ml) 1.2  0.8 1.1  0.1 1.2  1.0
TNF- (pg/ml) 2.05  0.06 2.40  0.16 2.67  0.13b
MCP-1 (pg/ml) 81.2  10.7 101.1  10.9 102.1  15.9
HGF (pg/ml) 235.3  45.8 293.1  49.0 478.9  65.4b,c
NGF (pg/ml) 4.71  0.99 10.86  3.10 13.38  3.72
ALT (UI/liter) 7  1 20  3 33  6b,c
AST (UI/liter) 11  1 13  1 21  5
ALP (UI/liter) 88  9 109  8 122  10
-GT (UI/liter) 9  1 18  2 33  6b,c
Data are mean  SEM. Differences between groups were analyzed by one-way ANOVA followed by Bonferroni’s post hoc tests. CRP
and SAA levels were logarithmically transformed for statistical analysis due to their non-normal distribution. OGTT, Oral glucose
tolerance test; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; -GT, -glutamyltransferase;
SAA, serum amyloid A.
a P  0.05 vs. lean.
b P  0.01 vs. lean.
c P  0.05 vs. obese NG.
d P  0.01 vs. obese NG.
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plasma creatinine (P  0.027), whereas a negative asso-
ciationwith urinary creatinine (P 0.018) as well as with
GFR (P  0.032) was observed.
In light of the divergent pathological consequences of
adipose tissuedistribution,weevaluated the effects ofobe-
sity and T2D on gene expression levels of YKL40 in VAT
and SAT. mRNA levels of YKL40 in VAT were signifi-
cantly increased in obese T2Dpatients comparedwith not
only the lean group (P  0.009) but also the obese NG
subjects (P  0.015) (Fig. 1B). Gene expression levels of
YKL40 in SAT followed the same trend, being higher in
T2D patients. However, no statistically significant differ-
ences were reached (P  0.065) (Supplemental Fig. 1A).
Moreover, YKL40 exhibited highest gene expression in
VAT compared with that of SAT (Supplemental Fig. 1B).
Based on the fact that YKL40 exhibited the highest gene
expression in VAT and given the relevance of this depot in
obesity-associated metabolic disturbances, the experi-
ments were focused on YKL40 in this location.
Because the obese T2D groupwas significantly older, a
group of 10 obeseNGvolunteerswith a similar age to that
of the obese patients with T2D has been included to in-
vestigate the effect of age on the gene expression levels of
YKL40 (Supplemental Table 2). Noteworthy, mRNA lev-
els of YKL40 in VAT were significantly increased (P 
0.05) in the obese T2D patients compared with both
groups of obese NG patients (Supplemental Fig. 2). Fur-
thermore, no differences in YKL40 expression levels were
detected between both obese NG groups (the former one
used who was significantly younger and the older one age
matched to the T2D individuals). This finding provides
evidence that the increased YKL40 expression levels are
independent of age.
YKL-40 protein levels in VAT followed the same trend
than YKL40 expression levels, being significantly higher
in obese T2D patients compared with lean controls (P 
0.032) and with obese NG patients. However, no statis-
tically significant differences were reached in the latter
comparison (P 0.090) (Fig. 1C).YKL40mRNAexpres-
sion in VAT was positively correlated with both protein
expression levels (P  0.039) and circulating concentra-
tions (P  0.021). Analogously to the significant associ-
ations observed with YKL-40 circulating concentrations,
a strong positive correlation (P 0.01) between gene and
protein expression levels with fasting insulin concentra-
tions was found, whereas a negative association with the
QUICKI index was evident (Table 2).
YKL-40 gene expression levels in adipocytes and
stromovascular fraction cells (SVFCs)
The presence of YKL-40 in sections of VAT was con-
firmed by immunohistological analysis (Fig. 2A). Both
adipocytes and SVFCs were immunopositive for YKL-40.
Becausemacrophages represent a relevant cell type source
in proinflammatory cytokine production and release, the
macrophage-specific marker CD68 was used to evaluate
the impact of resident macrophages in adipose tissue. As
expected, CD68 staining in VAT was localized mainly in
macrophages. YKL-40 labeling was detected in CD68-
positive cells, but noteworthy amarked staining inmature
adipocytes was also observed. As expected, the mRNA of
CD68 was up-regulated in VAT of obese NG compared
withLNindividuals (1.000.35vs.3.010.54arbitrary
units; P 0.010) and further increased in obese T2D pa-
FIG. 1. Circulating (A), gene (B), and protein (C) expression of YKL-40
in VAT of lean (LN), obese normoglycemic (OB-NG), and obese diabetic
(OB-T2D) volunteers. A, Bars represent the mean  SEM of YKL-40
plasma concentrations (LN: n  16; OB-NG: n  20; OB-T2D: n  17).
B, Real-time PCR analysis of YKL-40. The mRNA bars represent the
mean  SEM of the ratio between the gene expression and 18S rRNA.
The expression level in the LN subjects was assumed to be 1 (LN: n 
9; OB-NG: n  10; OB-T2D: n  10). C, Western blot analysis of YKL-
40 levels. Bars represent the mean  SEM of the ratio between YKL-40
and -actin. The expression in LN subjects was assumed to be 1 (LN:
n  9; OB-NG: n  10; OB-T2D: n  10). Differences between groups
were analyzed by one-way ANOVA followed by Bonferroni’s tests.
*, P  0.05, **, P  0.01 vs. LN, and †, P  0.05 vs. OB-NG.
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tients (4.05  0.73 arbitrary units; P  0.003 vs. LN). A
positive association between YKL40 and CD68 mRNA
levels was also detected (P  0.001).
Nodifferenceswere foundbetween the gene expression
levels of YKL40 in adipocytes and SVFCs obtained from
VAT samples of obese NG and T2D individuals (P 
0.566) (Fig. 2B). However, a tendency toward higher
mRNA expression levels was observed in adipocytes iso-
lated frompatientswithT2Dcomparedwith fat cells from
NG volunteers, although differences did not reach statis-
tical significance (Fig. 2C).
Circulating and adipose YKL-40 levels are related
to the chronic low-grade obesity-associated
inflammation
The inflammatory markers C-reactive protein (CRP),
fibrinogen, and IL-6 were significantly increased (P 
0.01) in both groups of obese patients comparedwith lean
subjects. In addition, obese patients with T2D exhibited
higher von Willebrand factor (vWF), TNF-, and he-
patocyte growth factor (HGF) concentrations (P 
0.01) than lean volunteers. Circulating concentrations
of YKL-40 were positively correlated (P 0.01) with the
inflammatory and prothrombotic markers IL-6, TNF-,
MCP-1, vWF, HGF, and nerve growth factor (Table 2,
Supplemental Table 3). Analogously, gene and protein ex-
pression levels in VAT were positively associated (P 
0.01) with the inflammatory markers CRP, IL-6, and
nerve growth factor. Gene expression levels of TNFA in
VAT were up-regulated in obese patients with T2D com-
pared with lean volunteers (1.00  0.49 vs. 3.19  0.66
arbitrary units; P 0.002) and a positive correlationwith
mRNA levels of YKL40 was found (P  0.01).
Multivariate linear regression analysis was performed
including age,HOMAindex (as insulin resistancemarker)
as well as TNF- and MCP-1 concentrations (as inflam-
matory markers) in the model due to their highly signifi-
cant associationwith the dependent variableYKL-40.Age
(P0.019),HOMA(P0.037), andMCP-1 (P0.024)
were significant independent determinants of YKL-40,
suggesting an influence of factors involved in glucose ho-
meostasis and inflammationoncirculating levelsofYKL-40.
Effect of weight loss on the circulating
concentration of YKL-40
To analyze the impact of therapeutic interventions
aimed at achieving weight loss in obese patients, the effect
on plasma YKL-40 concentrations induced by either bari-
atric surgery (RYGB) or a conventional lifestyle interven-
tion was examined. Both the short- and long-term effects
of weight loss after RYGB were evaluated. After an aver-
age 14-wk postsurgical period, RYGB patients experi-
enced a similar decrease in body weight than obese pa-
tients following a conventional hypocaloric diet (Table 3).
Surgical patients showed a significant decrease (P 
0.001) in body weight, body mass index (BMI), body fat
TABLE 2. Univariate analysis of the correlations between YKL-40 circulating concentrations and its VAT mRNA and
protein expression levels with variables of glucose homeostasis and inflammatory markers
Plasma YKL-40 VAT YKL-40 mRNA VAT YKL-40 protein
r P r P r P
Plasma YKL-40 — — 0.51 0.021 0.15 0.642
VAT YKL-40 mRNA 0.51 0.021 — — 0.50 0.039
VAT YKL-40 protein 0.15 0.642 0.50 0.039 — —
Age 0.44 0.002 0.02 0.994 0.16 0.551
BMI 0.20 0.184 0.39 0.059 0.18 0.493
BF 0.22 0.140 0.23 0.327 0.28 0.306
Waist 0.44 0.038 0.79 0.035 0.94 0.053
WHR 0.48 0.020 0.07 0.076 0.10 0.122
Glucose 0.53 <0.001 0.35 0.108 0.40 0.128
Insulin 0.46 0.005 0.62 0.004 0.67 0.008
HOMA 0.59 <0.001 0.45 0.056 0.43 0.127
QUICKI 0.47 0.006 0.63 0.004 0.52 0.054
Plasma creatinine 0.40 0.027 0.44 0.105 0.22 0.522
Urinary creatinine 0.45 0.018 0.20 0.774 0.83 0.022
GFR 0.40 0.032 0.32 0.363 0.20 0.666
CRP 0.33 0.071 0.70 0.002 0.78 <0.001
vWF 0.41 0.032 0.42 0.131 0.30 0.377
IL-6 0.32 0.028 0.63 0.003 0.73 0.004
TNF- 0.67 <0.001 0.16 0.948 0.26 0.278
MCP-1 0.56 <0.001 0.29 0.236 0.10 0.754
HGF 0.43 0.004 0.59 0.016 0.47 0.126
NGF 0.32 0.043 0.54 0.017 0.85 <0.001
Bold values highlight statistically significant P values.
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(BF), and waist circumference. Furthermore, a significant
improvement (P  0.05) in glucose and insulin concen-
trations togetherwith a decrease (P 0.01) in leptin levels
was detected. However, no differences in the circulating
concentrations of YKL-40 were observed. After an aver-
age of 13 months after the RYGB, patients experienced a
further significant decrease (P 0.0001) in body weight,
BMI, BF, and waist circumference as
well as a significant improvement in the
initial glycemia (P  0.006), insuline-
mia (P  0.047), HOMA (P  0.007),
and QUICKI (P 0.0001) indices (Ta-
ble3).As expectedafter the reduction in
BF, leptin concentrations were also sig-
nificantly reduced (P  0.012). Triglyc-
erides and total and low-density lipopro-
tein (LDL) cholesterol concentrations
were significantly lower (P  0.0001),
whereas high-density lipoprotein (HDL)
cholesterol levels were significantly in-
creased (P  0.005). Our data further
show that massive surgery-induced
weight loss after RYGB was not accom-
panied by statistically significant changes
in circulating levels of YKL-40 (Fig. 3A).
Noteworthy, the differences in YKL-40
concentrations were positively corre-
lated with the reduction in insulin con-
centrations even after BMI adjustment
(P 0.002).
After an average period of 14 wk,
obese patients following the conven-
tional hypocaloric diet experimented
significant decreases (P  0.001) in
weight, BMI, BF, waist circumference,
WHR, and triglycerides as well as a sig-
nificant improvement in glycemia (P
0.035) and the QUICKI (P  0.027)
(Table 3). The inflammatory markers
CRP and fibrinogen decreased, although
differences did not reach statistical signif-
icance.However, thediet-inducedweight
lossproducedastatistically significant re-
duction (P  0.040) in circulating
YKL-40 concentrations (Fig. 3B).
Discussion
VAT secretes a wide range of signaling
proteins collectively called adipokines,
which are directly involved in the
pathogenesis of obesity-related derangements (1). Our re-
sults show increased mRNA and protein expression of
YKL-40 in human VAT in patients with T2D. To our
knowledge, this is the first study describing elevated
mRNAandprotein expression levels ofYKL-40 inVAT in
human obesity-associated T2D. Our study further pro-
vides evidence that obese patients with T2D exhibit in-
FIG. 2. Analysis of YKL-40 in adipocytes and SVFCs. A, Immunohistochemistry of YKL-40 and
CD68 in VAT. A strong positivity (brown staining) was observed for YKL-40 in both fully
mature adipocytes and cells of the SVFCs. No immunoreactivity was found without the
primary antibody (negative control). Images are representative of immunostaining in six
sections of VAT from obese normoglycemic (OB-NG) and obese diabetic (OB-T2D) subjects
(scale bar, 50 m). B, Comparison of YKL-40 gene expression in adipocytes (ADIPOC) and
SVFCs isolated from the VAT of obese patients. Bars represent the mean  SEM of the ratio
between the gene expression and 18S rRNA. The expression level in adipocytes was assumed
to be 1 (adipocytes: n  9; SVFCs: n  11). C, Differential expression of YKL-40 gene in
visceral adipocytes obtained from obese patients with normoglycemia (NG) or T2D. Bars
represent the mean  SEM of the ratio between gene expression and 18S rRNA. The
expression level in OB-NG was assumed to be 1 (OB-NG: n  8; OB-T2D: n  6). Statistical
differences were assessed by a two-tailed unpaired Student’s t test.
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creased circulating concentrations of YKL-40, which is in
agreement with previous studies (9, 11). Different cross-
sectional studies concluded thatWHR is a better predictor
of cardiovascular and T2D risk factors than BMI (16). In
this regard, in our study patients with higher WHR
showed increased levels of circulating YKL-40 levels.
Moreover, the positive correlation between gene expres-
sion levels and circulating concentrations of YKL-40 sug-
gests that VAT contributes to the increased plasma
YKL-40 levels in obesity-associated T2D. Visceral adipo-
cytes are metabolically more active displaying huge dif-
ferences in gene expression levels compared with sc adi-
pocytes. The production and release of inflammatory
cytokines is reportedly increased in VAT, suggesting that
an excess visceral adiposity is related to amore proinflam-
matory state (2). Noteworthy, it has been shown that
YKL40 gene expression is higher in visceral than sc SVFCs
(17), probably due to the greater infiltration of macro-
phages taking place in omental fat. Moreover, high
mRNAandprotein expression levels ofYKL-40analyzing
separately subpopulations ofmacrophages in different tis-
sues obtained from diverse inflammatory processes and
extracellular matrix remodeling conditions have been de-
scribed (4).
In our study, the presence of YKL-40 by immunohis-
tochemistry in human VAT is clearly shown. YKL-40 la-
beling was detected in CD68-positive macrophages as
might be expected but, contrarily to other studies (17), a
marked staining in fully mature adipocytes was also ob-
served. Moreover, no differences in mRNA expression of
YKL40 between adipocytes and SVFCs were detected. In
this regard, gene expression levels of YKL40 from prea-
dipocytes had been reported to be remarkably low com-
pared with those of macrophages (17). A plausible expla-
nation may depend on a YKL40 gene expression increase
taking place during the differentiation process from prea-
dipocytes to mature adipocytes. Our findings suggest that
both macrophages and adipocytes are involved in the se-
cretion of YKL-40. Because mRNA levels of YKL40 and
CD68 were positively correlated, YKL40 expression lev-
elsmay reflect the degree ofVATmacrophage infiltration.
To gain more insight into the source of production, we
further analyzed the gene expression levels of YKL40 in
isolated adipocytes, which revealed a higher expression in
patients with T2D compared with obese NG volunteers,
thereby suggesting a more pronounced contribution of
visceral adipocytes to the elevated concentrations of
YKL-40 observed in T2D.






(13 months) Before WL
After WL
(14 wk)
n 26 26 26 20 20
Age (yr) 41  2 41  2 42  2 41  3 42  3
Body weight (kg) 122  5 105  4a 85  3a 108  7 88  4a
BMI (kg/m2) 47.0  1.8 40.4  1.5b 33.2  1.2a 36.6  2.1 30.1  1.3a
BF (%) 54.1  0.8 51.7  1.0b 42.0  1.4a 41.9  2.0 33.4  2.5a
Waist (cm) 126.8  2.0 114.4  2.0b 100.0  3.2b 114.4  4.5 100.5  3.2b
WHR 0.89  0.02 0.89  0.03 0.87  0.03 0.96  0.02 0.93  0.02c
Fasting glucose (mg/dl) 108.6  8.0 88.7  2.0b 89.7  3.0b 96.0  2.3 88.0  1.9c
Fasting insulin (U/ml) 21.0  3.1 15.2  2.6c 11.2  2.9c 14.5  3.2 8.6  1.3
HOMA 6.0  1.6 3.4  0.7c 2.7  0.9b 3.4  0.8 1.9  0.3
QUICKI 0.31  0.01 0.33  0.01b 0.35  0.01a 0.33  0.01 0.36  0.01c
Triglycerides (mg/dl) 114  12 100  20 86  7 117  14 80  8a
Cholesterol (mg/dl) 210  9 173  9 165  6a 204  9 177  7c
LDL cholesterol (mg/dl) 142  8 110  6 99  5a 127  8 109  5
HDL cholesterol (mg/dl) 44  3 43  4 48  2b 54  3 52  3
Leptin (ng/ml) 71.0  6.1 31.8  1.4b 28.9  4.2b 35.0  6.8 13.4  2.9
CRP (mg/liter) 9.1  1.2 — 4.9  1.6 9.0  3.0 4.9  3.1
Fibrinogen (mg/dl) 378  20 380  38 338  14 398  26 384  84
ALT (UI/liter) 26  4 — 23  2 30  5 18  3b
AST (UI/liter) 18  4 — 17  2 17  2 14  1c
ALP (UI/liter) 116  9 — 104  12c 99  5 83  6c
-GT (UI/liter) 28  5 — 14  2 24  3 15  3c
Data are mean  SEM. Differences between groups were analyzed by two-tailed paired t tests. CRP levels were logarithmically transformed for
statistical analysis due to their nonnormal distribution. ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
-GT, -glutamyltransferase; WL, weight loss.
a P  0.0001 vs. before WL.
b P  0.01 vs. before WL.
c P  0.05 vs. before WL.
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In agreement with previous results (9–11), increased
YKL-40 levels in patients with T2Dwere observed. These
data together with the positive correlation of plasma
YKL-40 with fasting glucose, insulin, and the HOMA in-
dex as well as the negative correlation with the QUICKI
highlight a link between YKL-40 and hyperglycemia and,
consequently, with the development of insulin resistance
and T2D. In accordance with this, a correlation between
YKL-40 and glycemic-related parameters such as hemo-
globin A1c has been also shown (12). Patients with type 1
diabetes exhibit a positive association between increased
YKL-40 levels and elevated albuminuria, indicating that
YKL-40 may be a marker of renal vascular damage pro-
gression (12). In this sense, we found that increasing con-
centrations of YKL-40 were associated with a decline in
GFR, pointing to a plausible implication of YKL-40 in the
impaired kidney function in obese T2D patients, given the
need for its renal excretion. Moreover, a positive correla-
tion of YKL-40with circulating creatinine concentrations
together with a negative correlation with urinary creati-
nine levels was detected in the univariate analysis. No as-
sociationswith obesity-related variableswere identified in
the study. In this regard, Nielsen et al. (9) did not find a
correlation between YKL-40 and BMI.
ReducedYKL-40 levels in obese patients after bariatric
surgeryhavebeendescribed indicating anassociationwith
adipose tissue and weight loss (10). In the present study,
the impact on YKL-40 levels of weight loss achieved by
both RYGB and a conventional lifestyle intervention has
been evaluated. Obese patients either after the surgical
procedure or following a conventional hypocaloric diet
experienced a similar decrease in body weight after a
short-term period. Interestingly, diet-induced weight loss
was followed by a reduction in YKL-40 concentrations,
whereas no differences in surgically treated patients were
observed. To gain more insight into the effects of RYGB,
changes in YKL-40 concentrations after a long-term fol-
low-up were also assessed. Oppositely to Hempen et al.
(10), in our study, a similar surgery-induced weight loss
did not induce a statistically significant reduction in cir-
culating levels ofYKL-40.The studybyHempen et al. (10)
included only 17 patients with an unbalanced gender se-
lection and the specific bariatric surgery intervention was
not specified. In this sense, mean changes in risk factors
reportedly vary according to the specific type of surgical
procedure used (18). Noteworthy, a positive correlation
between differences in YKL-40 levels and changes in in-
sulin concentrations in RYGB was observed, which high-
lights the role ofYKL-40 in relationwith insulin resistance
rather than with obesity development. Similarly, it has
been reported that TNF- concentrations remained un-
changed after weight loss after bariatric surgery (19),
whereas its levels decreased after weight loss induced by a
hypocaloric diet (20). Plausible explanations for both the
YKL-40 and TNF- findings relate to the stressful effects
caused by relative starvation or surgery itself (21). Alter-
natively, due to the fact that our patients remained obese
and with higher BMI and BF compared with the patients
on the hypocaloric diet, the potential existence of a thresh-
old level for adiposity before any effect on the circulating
concentrations of these adipokines becomes evident. In
this sense, we showed that obese patients on the hypoca-
loric diet experienced a significant decrease in WHR,
whereas patients who underwent bariatric surgery did not
exhibit significantdifferences.Due to the fact thatYKL-40
concentrations are closely correlated withWHR, the lack
of a WHR reduction in patients after RYGB may be in-
fluencing the absence of statistically significant YKL-40
decrease. Nonetheless, this heterogeneous response and
the differences in the inflammatory response after these
two ways of weight loss still remain to be clarified. In
line with this, an increase in osteopontin plasma con-
centrations concomitantly to weight loss after bariatric
surgery and independent from the insulin sensitivity im-
provement and the decrease in inflammatory markers
has been observed (22). In addition, the metabolic
changes taking place in the gastrointestinal tract after
RYGB may be influencing the lack of decrease in
YKL-40 concentrations.
FIG. 3. Comparison of plasma YKL-40 concentrations determined in
obese patients before and after weight loss (WL) achieved by RYGB or
a conventional lifestyle intervention. Effect after RGYB (n  26) (A) and
after a conventional hypocaloric regimen (n  20) (B) is shown. Values
are means  SEM. Statistical differences were assessed by two-tailed
paired Student’s t tests. *, P  0.05 vs. prediet values.
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Because insulin resistance in obese patients is partially
caused by a chronic low grade-inflammatory state, our
results indicate that YKL-40 might play a role in this pro-
cess. Our findings in relation to inflammation are in line
with previous reports where an association with MCP-1
was detected (10). A positive association of YKL-40 with
TNF- and HGF, well-established markers of chronic in-
flammation,was observed in the present study.Moreover,
YKL40 gene expression levels were positively correlated
with VAT TNFA mRNA. No association between
YKL-40 and the acute phase reactants, CRP and serum
amyloid A, was observed in the present study, implying
that elevated YKL-40 levels are independent from the in-
creased concentrations of both inflammatory markers.
Our finding is in accordance with another study (11), al-
though a strong association ofYKL-40withCRPhas been
described in patients with rheumatoid arthritis as well as
in elderly women (23, 24). In this regard, we show that
YKL-40 gene and protein expression levels in VAT are
associated with IL-6 and CRP. Multivariate linear regres-
sion analysis identified MCP-1 and HOMA as indepen-
dent factors predicting circulating YKL-40, suggesting a
marked influence of glucose homeostasis and inflamma-
tion onYKL-40 regulation. This leads to a possible role of
YKL-40 in insulin resistance in relation to its direct or
indirect effects on inflammation.YKL-40 is a secretedpro-
tein, suggesting that its sites of actions aremost likely to be
extracellular. However, the activation of cytoplasmic sig-
nal transduction pathways suggests that YKL-40 interacts
with one or several signaling components on the plasma
membrane. Specific cell-surface, soluble receptors or po-
tential ligands for YKL-40 have not been identified yet. In
this regard, the study of the actual YKL-40 receptors to-
gether with the signaling pathways triggered by these re-
ceptors may help to better understand the role of YKL-40
in adipose tissue.
In summary, we have identified the up-regulation of
gene and protein expression levels of YKL-40 in VAT as
well as an association with its circulating concentrations,
suggesting the contribution of visceral fat to the increased
circulating YKL-40 levels in obesity-associated T2D. The
decrease in insulin concentrations observed in RYGB-in-
duced weight loss was correlated with the reduction in
YKL-40 levels, reinforcing its involvement in glucose ho-
meostasis. Only diet-induced weight loss was able to sig-
nificantly reduce circulating YKL-40 concentrations in
obese patients in our study. The association between
YKL-40 with different proinflammatory markers high-
lights an involvement in the low-grade chronic inflamma-
tion accompanying obesity-associated T2D. The biologi-
cal function of YKL-40 is not yet clear, but our results
strengthen the view for an involvement of YKL-40 in the
low-grade inflammation associated with the development
of T2D.
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